We used time series of CA-125 in 791 patients with high-grade serous ovarian cancer (HGSOC) from the Australian Ovarian Cancer Study to quantify the evolution of resistance and aggressiveness as a response to therapy in individual patients to predict the dynamics of CA-125 and the survival outcomes. This evidence concerns the gene MUC16 and ovarian carcinoma.